InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Tuesday morning. The firm issued a sell rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and set a $4.50 target price on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Stock Performance

NYSE:NSPR opened at $3.01 on Tuesday. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.42. The stock has a fifty day moving average of $2.57 and a 200 day moving average of $2.62. The firm has a market capitalization of $78.50 million, a price-to-earnings ratio of -4.03 and a beta of 0.93.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same quarter last year, the business posted ($0.15) earnings per share. Equities analysts forecast that InspireMD will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InspireMD

Hedge funds and other institutional investors have recently made changes to their positions in the business. Parkman Healthcare Partners LLC bought a new stake in InspireMD in the third quarter valued at $279,000. Affiance Financial LLC purchased a new stake in shares of InspireMD in the 3rd quarter worth about $492,000. Finally, Rosalind Advisors Inc. boosted its stake in shares of InspireMD by 266.4% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after purchasing an additional 1,827,579 shares in the last quarter. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.